Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

U.S. Preparedness and Response to Increasing Clade I Mpox Cases in the Democratic Republic of the Congo - United States, 2024

Jennifer H McQuiston et al. MMWR Morb Mortal Wkly Rep. .

Abstract

Clade I monkeypox virus (MPXV), which can cause severe illness in more people than clade II MPXVs, is endemic in the Democratic Republic of the Congo (DRC), but the country has experienced an increase in suspected cases during 2023-2024. In light of the 2022 global outbreak of clade II mpox, the increase in suspected clade I cases in DRC raises concerns that the virus could spread to other countries and underscores the importance of coordinated, urgent global action to support DRC's efforts to contain the virus. To date, no cases of clade I mpox have been detected outside of countries in Central Africa where the virus is endemic. CDC and other partners are working to support DRC's response. In addition, CDC is enhancing U.S. preparedness by raising awareness, strengthening surveillance, expanding diagnostic testing capacity for clade I MPXV, ensuring appropriate specimen handling and waste management, emphasizing the importance of appropriate medical treatment, and communicating guidance on the recommended contact tracing, containment, behavior modification, and vaccination strategies.

PubMed Disclaimer

Conflict of interest statement

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Christopher K. Brown reports uncompensated participation on the Prevention, Preparedness, and Response Consortium Training Academy Advisory Board. No other potential conflicts of interest were disclosed.

Figures

FIGURE 1
FIGURE 1
Suspected clade I mpox cases and deaths — Democratic Republic of the Congo, January 1, 2023–April 14, 2024 * Reporting of data from multiple sources might result in minor discrepancies between the numbers of cumulative cases and deaths reported to CDC by the Democratic Republic of the Congo Ministry of Health and those that appear in the figure.
FIGURE 2
FIGURE 2
Number of suspected clade I mpox cases, by province — Democratic Republic of the Congo, January 1, 2023–April 14, 2024
FIGURE 3
FIGURE 3
Age distribution of suspected clade I mpox cases and deaths — Democratic Republic of the Congo, January 1, 2023–April 14, 2024

References

    1. McQuiston JH, Braden CR, Bowen MD, et al. The CDC domestic mpox response—United States, 2022–2023. MMWR Morb Mortal Wkly Rep 2023;72:547–52. 10.15585/mmwr.mm7220a2 - DOI - PMC - PubMed
    1. Bunge EM, Hoet B, Chen L, et al. The changing epidemiology of human monkeypox—a potential threat? A systematic review. PLoS Negl Trop Dis 2022;16:e0010141. 10.1371/journal.pntd.0010141 - DOI - PMC - PubMed
    1. Pittman PR, Martin JW, Kingebeni PM, et al.; Kole Human Mpox Infection Study Group. Clinical characterization and placental pathology of mpox infection in hospitalized patients in the Democratic Republic of the Congo. PLoS Negl Trop Dis 2023;17:e0010384. 10.1371/journal.pntd.0010384 - DOI - PMC - PubMed
    1. Kibungu EM, Vakaniaki EH, Kinganda-Lusamaki E, et al.; International Mpox Research Consortium. Clade I–associated mpox cases associated with sexual contact, the Democratic Republic of the Congo. Emerg Infect Dis 2024;30:172–6. 10.3201/eid3001.231164 - DOI - PMC - PubMed
    1. Masirika LM, Udahemuka JC, Schuele L, et al. Ongoing mpox outbreak in Kamituga, South Kivu province, associated with monkeypox virus of a novel clade I sub-lineage, Democratic Republic of the Congo, 2024. Euro Surveill 2024;29(11):2400106. 10.2807/1560-7917.es.2024.29.11.2400106 - DOI - PMC - PubMed

MeSH terms